EPTIFIBATIDE

Course overview

EPTIFIBATIDE IS A GLYCOPROTEIN IIB/IIIA CLASS PLATELET INHIBITOR DRUG USED TO REDUCE ISCHEMIC CARDIAC EVENTS IN SPECIFIC PATIENT POPULATIONS. A PROTEIN FOUND IN THE VENOM OF A SOUTHEASTERN PYGMY RATTLESNAKE IS USED TO MAKE EPTIFIBATIDE. FDA HAS APPROVED THIS MEDICINE FOR THE MEDICAL MANAGEMENT OF UNSTABLE ANGINA (UA) AND NON-ST ELEVATION MYOCARDIAL INFARCTION (NSTEMI). FDA ALSO APPROVED EPTIFIBATIDE FOR PATIENTS UNDERGOING PCI, INCLUDING INTRACORONARY STENTING. THE IMPACT-II TRIAL PROVED THAT EPTIFIBATIDE USE WITH HEPARIN AND ASPIRIN REDUCES ISCHEMIC EVENTS FOLLOWING A PERCUTANEOUS CORONARY INTERVENTION (PCI), ESPECIALLY IN INDIVIDUALS WITH UNSTABLE ANGINA. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, ADMINISTRATION, ADVERSE EFFECTS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, MONITORING, AND TOXICITY OF EPTIFIBATIDE.